KRAS G12C inhibition using MRTX1257: a novel radio-sensitizing partner.

Pierre-Antoine LaurentMarina MilicClément QuevrinLydia MezianiWinchygn LiuDaphné MorelNicolas SignolleCéline ClémensonAntonin LevyMichele MondiniEric Deutsch

Published in: Journal of translational medicine (2023)

mutated tumors, which are the most represented in NSCLC with 14% of patients harboring this mutational profile.

Keyphrases

end stage renal disease
small cell lung cancer
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
wild type
patient reported outcomes
tyrosine kinase
epidermal growth factor receptor
antiretroviral therapy